Prostate Cancer
To Navy veteran Matthew Roach, the bell is more than a piece of metal—it’s a message that hope is alive. Read More ›
Low-grade prostate cancer isn’t always low risk; factoring in all data reveals some patients may be undertreated. Read More ›
A look at estimates of life expectancy in prostate cancer compared with other causes, using advanced statistical modeling. Read More ›
Researchers from the Fralin Biomedical Research Institute (Virginia Tech) Cancer Research Center in Washington, DC, have identified a group of cells called macrophages that, instead of protecting the body, appear to shield tumors from attack and promote tumor metastasis. Read More ›
A newly identified gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy. Read More ›
September is Prostate Cancer Awareness Month. This awareness campaign, coupled with former President Joe Biden’s prostate cancer diagnosis earlier this year, presents an opportunity to educate people about the disease—and to highlight how oncology professionals make a difference in prostate cancer care. Read More ›
The Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among Black men with early-stage disease, according to results presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington, DC. Read More ›
Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
On November 16, 2023, the FDA approved a supplemental new drug application for enzalutamide (Xtandi; Astellas Pharma and Pfizer), an androgen receptor signaling inhibitor, for the treatment of nonmetastatic, castration-sensitive prostate cancer with biochemical recurrence (BCR) at high risk for metastasis (high-risk BCR). Read More ›
According to the American Cancer Society, approximately 288,300 men in the United States will be diagnosed with prostate cancer in 2023 and 34,700 deaths will be attributed to the disease. September is Prostate Cancer
Awareness Month, a time designated
to help people learn more about the
disease and to support those who are
affected. Read More ›